| Title |
Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2015
|
| DOI | 10.2147/tcrm.s66680 |
| Pubmed ID | |
| Authors |
Jeanetta W Frye, David A Peura |
| Abstract |
The management of gastroesophageal reflux disease (GERD) has been revolutionized with the development of proton pump inhibitors (PPIs). Unfortunately, due to the inherent pharmacokinetic and pharmacodynamic profiles of conventional PPIs, many patients continue to suffer from symptoms related to GERD despite appropriate use of PPIs. Dexlansoprazole MR is a PPI with a unique dual delayed-release delivery system that has been designed to address the unmet needs in GERD management. Specifically, dexlansoprazole MR addresses limitations with short plasma half-life and need for meal-associated dosing, characteristic of conventional PPIs. In addition, dexlansoprazole MR has been shown to be effective in several specific clinical situations. These include coadministration with clopidogrel, healing of all grades of erosive esophagitis, improvement in reflux-related quality of life, step down to once-per-day dosing, and treatment of Helicobacter pylori infections. Furthermore, dexlansoprazole MR has been found to induce symptom improvement in patients with nonerosive esophageal reflux disease, nocturnal heartburn and GERD-related sleep disturbance, and regurgitation. Overall, dexlansoprazole MR is a unique and useful tool in the management of GERD. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 14% |
| Researcher | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Other | 8 | 22% |
| Unknown | 11 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
| Nursing and Health Professions | 1 | 3% |
| Unspecified | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 15 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2015.
All research outputs
#17,432,668
of 25,576,275 outputs
Outputs from Therapeutics and Clinical Risk Management
#924
of 1,324 outputs
Outputs of similar age
#172,199
of 287,373 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#46
of 53 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,324 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,373 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.